Syneos Health

SSU & Regulatory Specialist II - Russian Federation

Salary
Negotiable
Posted
04 Dec 2018
Closes
04 Jan 2019
Ref
PL-18009846

JOB RESPONSIBILITIES

 

  • Responsible for the quality deliverables at the country level; follows project requirements and applicable country rules, with moderate oversight from the SSU Country Manager. 
  • Works within the forecasted submission/approval timelines and ensures they are complied with and tracks milestone progress in agreed upon SSU tracking system in real time; if forecasted timelines are not reached:  investigates and provides clear rationale for delays, provides support on contingency plan to mitigate impact, and escalates the issue as soon as identified. 
  • Monitors basic financial aspects of the project and the number of hours/tasks available per contract; escalates discrepancies in a timely fashion. 
  • Reviews and complies with Standard Operating Procedures (SOPs) and Work Instructions (WI) in a timely manner, keeps training records updated accordingly and ensures timesheet compliance. 
  • Supports continuous improvement of quality in all Site Start-Up (SSU) components at the country level where assigned (submissions, essential document collection, communication to Competent Authorities and ECs, etc.).
  • Ensure all relevant documents are submitted to the Trial Master File (TMF) as per Company SOP/Sponsor requirements.

QUALIFICATION & REQUIREMENTS

  • Bachelor’s Degree,
  • Detailed understanding of clinical trial process across Phases II-IV and ICH GCP.
  • Fluent Russian as well as fluent English
  • Demonstrated ability to work independently as well as part of a team. 

We have a comprehensive benefits package and offer highly competitive remuneration.

Join a game-changing company that is reinventing the way therapies are developed and commercialized. Created through the merger of two industry leading companies, INC Research and inVentiv Health, we bring together more than 22,000 clinical and commercial minds to create a better, smarter, faster way to get biopharmaceutical therapies into the hands of patients who need them most.